479 related articles for article (PubMed ID: 19188814)
1. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
Wen YH; Yee H; Goswami S; Shukla PS
Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.
Daponte A; Kostopoulou E; Papandreou CN; Daliani DD; Minas M; Koukoulis G; Messinis IE
Anticancer Res; 2008; 28(3B):1905-10. PubMed ID: 18630479
[TBL] [Abstract][Full Text] [Related]
3. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
6. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
7. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase 2 expression in serous tumors of the ovary.
Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
[TBL] [Abstract][Full Text] [Related]
9. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
[TBL] [Abstract][Full Text] [Related]
11. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
12. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
Rodabaugh KJ; Mhawech-Fauceglia P; Groth J; Lele S; Sood AK
Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
[TBL] [Abstract][Full Text] [Related]
13. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
16. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
Wang X; Wei Z; Gao F; Zhang X; Zhou C; Zhu F; Wang Q; Gao Q; Ma C; Sun W; Kong B; Zhang L
Anticancer Res; 2008; 28(5B):2991-6. PubMed ID: 19031945
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas and FasL in human serous ovarian epithelial tumors.
van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
[TBL] [Abstract][Full Text] [Related]
20. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.
Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M
Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
